Enter HPOP ID in Therapeutics Order Request Form
When requesting COVID-19 monoclonal antibodies in the Vaccine Allocation & Ordering System (VAOS), providers who have an HPOP State PIN should enter the numbers from it in the Amerisource Bergen Account Number field. For example, if your HPOP State PIN is TXA123456, enter 123456. Providers who do not have an HPOP account should contact therapeutics@dshs.texas.gov to enroll.
Reminder: Sotrovimab EUA Changes: Decreased Time for Administration and Updated Efficacy Data
The Emergency Use Authorization (EUA) for COVID-19 therapeutic sotrovimab has been updated to include the most recent data on its efficacy against various variants.
Moreover, there has been a decrease in the time for administration from the onset of symptoms. Providers now must administer sotrovimab within seven (7) days from the onset of symptoms, instead of ten (10) days.
Please review the sotrovimab EUA Fact Sheet for more details.
Change in Paxlovid and Molnupiravir Allocation Process
Pharmacies interested in providing Paxlovid and molnupiravir should be aware of an upcoming change in the allocation process for these antivirals. Starting next cycle (week of March 21, 2022), DSHS will allocate Paxlovid and/or molnupiravir based on emailed requests instead of doing case-based allocations and automatic ordering/shipping.
To obtain additional Paxlovid and/or molnupiravir for your facility, please email therapeutics@dshs.texas.gov with the number of courses requested of the specified product.
- Please include the full name of the facility and HPOP State PIN (e.g., TXA123456)
- Request quantities in multiples of 20 for Paxlovid and 24 for molnupiravir.
- Inventory reporting in HPOP must be current.
-
These are requests. Oral antivirals are subject to allocation and the request may not be filled in full.
- Please email requests by 5:00PM on the Thursday prior to the allocation. See dates below.
Reminder: FDA Authorizes Revisions to Evusheld Dosing
The U.S. Food and Drug Administration (FDA) has revised the emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab), increasing the initial authorized dose to 300 mg of tixagevimab and 300 mg of cilgavimab. Patients who have already received the previously authorized dose (150 mg of tixagevimab and 150 mg of cilgavimab) should receive an additional dose of 150 mg of tixagevimab and 150 mg of cilgavimab as soon as possible to raise their monoclonal antibody levels to those expected for patients receiving the higher dose.
For more information, please review DSHS’ February 25th communication, “Evusheld Dosage Update.”
Please report inventory and administration in HPOP by cartons (150 mg tixagevimab/150 mg cilgavimab). The patient receiving the larger initial dose (300 mg each of tixagevimab/cilgavimab) would be reported as TWO units (cartons or courses) administered while the repeated, smaller dose (150 mg tixagevimab/150 mg cilgavimab) would be reported as ONE unit administered.
Expert Tip: Use the “Willing to Accept Another Product” Checkbox in VAOS
The option to directly place order requests for bebtelovimab has not yet been added to VAOS. However, providers who wish to be considered for bebtelovimab allocations should place an order request for sotrovimab in VAOS and check the box “Willing to Accept Another Product” to indicate they are willing to accept bebtelovimab.
Please contact the DSHS therapeutics team by email at therapeutics@dshs.texas.gov or by phone at (833) 832-7068, option 0 with any questions related to placing order requests for bebtelovimab.
For more information, please review DSHS’ February 12th email, “Bebtelovimab - COVID-19 monoclonal antibody receives EUA.”
|
